MarginsXMarginsX
Home › Markets › Health Care › PULM

Pulmatrix Inc. (PULM)

PULM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.33
+2.31% on the day
Market cap
$4.9M
Nano cap
Revenue · 2024
$7.8M
+7.0% on 2023
Net income · 2024
-$9.6M
-122.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K/A (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/0001493152-26-028902-index.htm. Net income: SEC 10-K/A (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerPULM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001574235
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$7.8M
Net income-$9.6M
Operating income-$9.8M
Net margin-122.5%
Operating margin-125.1%
Revenue growth+7.0%
Cash$9.5M
Total assets$9.9M
P/E (computed)Net income was not positive
P/S (computed)0.6×

Warning signs

Cash runway
6.7 months
$2.2M cash at June 30, 2026
Share count, 1 year
0.0%
2025-07-31 to 2026-08-13 · 0.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Management believes that, given the Company's current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the Merger."
10-Q 2026-08-13
Cash and burn$2.2M cash; operating cash flow -$978K a quarter.Report 2026-06-30
Shares outstanding3,652,285 (2026-08-13); 3,652,285 a year earlier; 3,652,285 three years earlier.Cover page 2026-08-13
Reverse splits, 3 years1; latest on 2026-03-27Source 2026-03-27
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., New York, New York, United StatesPCAOB Form AP 2026-03-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$1.0M-$1.1M$2.2MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$1.2M-$1.1M$3.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
Not filed-$928K-$706K$4.1MNo debt tagsNeeds four quarters10-K/A 2026-06-16
Q3 2025
2025-09-30
Not filed-$877K-$1.0M$4.8MNo debt tagsNeeds four quarters10-Q 2025-10-16
Q2 2025
2025-06-30
Not filed-$1.5M-$1.9M$5.8MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$1.8M-$1.8M$7.7MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
$3K-$2.0M-$1.3M$9.5MNo debt tags$7.8M10-K/A 2026-06-16
Q3 2024
2024-09-30
$366K-$2.6M-$3.1M$10.8MNo debt tags$10.0M10-Q 2025-10-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-26
Latest annual report10-K/A2026-06-16
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-10-27
Latest proxyDEFA14A2026-10-07

Source: SEC EDGAR submissions feed, 654 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.5%
1 month-6.5%
3 months-14.6%
Year to date-42.2%
1 year-73.6%
From 52-week high-72.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
SCNXScienture Holdings Inc.$2.99+3.10%$4.9M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
NCNANuCana plc American Depositary Share$0.8631-7.46%$4.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier